Kite updates KTE-C19 timeline

In its 3Q16 earnings report, Kite Pharma Inc. (NASDAQ:KITE) said it hopes to begin by YE16 the submission of a rolling BLA to FDA for its chimeric antigen receptor (CAR) T cell therapy KTE-C19 to treat non-Hodgkin's lymphoma (NHL). It hopes to complete the submission by the end of 1Q17 and launch the therapy next year.

Kite said it plans to seek the therapy's broad approval to treat multiple types of aggressive NHL, including chemorefractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (FL) and primary mediastinal B cell lymphoma (PMBCL)...